Researchers at Sichuan University in Chengdu, China, have injected the first CRISPR-edited cells into a patient. The procedure is part of a study designed to test the technique’s safety for use… Read More
To many, immunotherapies — treatments that use a patient’s immune system to fight cancer— sound like something from an episode of Star Trek. In CAR T cell therapy, for example, a… Read More
A study published today on a Juno Therapeutics immunotherapy treatment for blood cancers shows that the drug and others like it could be more effective and less toxic than other treatments. The… Read More
Take a quick browse through Seattle’s biotech scene, and you’ll notice a pattern. Immunotherapy — using the body’s immune system to fight cancer — is the hottest topic in biotechnology nowadays, and it… Read More
It’s been a busy quarter for Juno Therapeutics with several different immunotherapy trials underway and a big hiring push as it expands research capabilities. The Seattle-based biotech giant, which re-engineers the… Read More
Seattle-based Aptevo Therapeutics completed a spinoff from Emergent BioSolutions Monday, making a debut in the public markets as a standalone company. They are the second Seattle-area biotech company to go public… Read More
Seattle-based Juno Therapeutics says it’s resuming a clinical trial of its immunotherapy treatment, a week after the Food and Drug Administration ordered a hold due to the deaths of three… Read More
Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of next-generation therapies that tweak the body’s immune system to fight… Read More
Adaptive Biotechnologies, the heavily-funded Seattle bioinformatics company, today announced that Diego Miralles will become the president of a new division of the company called Adaptive Therapeutics. Miralles will work to build out the… Read More